Results 41 to 50 of about 605,792 (294)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source

Carcinoid Heart Disease: How to Diagnose and Treat in 2020?

Clinical Medicine Insights: Cardiology, 2020
Neuroendocrine tumors (NETs, originally termed “carcinoids”) create a relatively rare group of neoplasms with an approximate incidence rate of 2.5 to 5 cases per 100 000 persons.
Barbara Bober, Marek Saracyn, Maciej Kołodziej, Łukasz Kowalski, Elżbieta Deptuła-Krawczyk, Waldemar Kapusta, Grzegorz Kamiński, Olga Mozenska, Jacek Bil   +8 more
doaj   +1 more source

Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly

Journal of the Formosan Medical Association, 2016
The aim of the present study was to evaluate the serial changes of GH and IGF-1 in seven patients with naïve, active acromegaly following presurgical treatment of the somatostatin analog pasireotide long-acting release (LAR) and octreotide LAR.
Jan-Shun Chang, Ham-Min Tseng, Tien-Chun Chang   +2 more
doaj   +1 more source

Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?

Genel Tıp Dergisi, 2022
Objective: Somatostatin analogs (SSA) are used in treating low-grade neuroendocrine tumors, mainly because of their antiproliferative effect. 68Ga tetraazacyclododecantetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT as somatostatin receptor ...
Çağlagül Erol, Ahmet Volkan Çelik, Özlem Şahin, Gonca Kara Gedik, Hasan Önner, Farise Yılmaz   +5 more
doaj   +1 more source

Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide [PDF]

, 1995
Recently, we developed a technique that allows the in vivo visualization in man of somatostatin receptor-positive neuroendocrine tumors after i.v.
Breeman, W.A.P. (Wouter), Hofland, L.J. (Leo), Koetsveld, P.M. (Peter) van, Lamberts, S.W.J. (Steven), Waaijers, M. (Marlijn), Zuyderwijk, J.   +5 more
core   +1 more source

Progress in the formulation and delivery of somatostatin analogs for acromegaly.

Therapeutic delivery, 2017
A 14 amino acid cystin bridge containing neuropeptide was discovered in 1973 and designated as growth hormone-inhibiting hormone, in other words, somatostatin.
Sarinj Fattah, David J Brayden
semanticscholar   +1 more source

Characterization of Somatostatin Receptor Subtype 2 Expression in Stably Transfected A-427 Human Cancer Cells

Molecular Imaging, 2007
Although radiolabeled somatostatin analogs have become highly prevalent in the diagnosis and treatment of somatostatin receptor subtype (sst)-positive tumors, there are relatively few options with respect to sst-positive tumor cell lines and animal ...
Jesse J. Parry, Martin Eiblmaier, Rebecca Andrews, Laura A. Meyer, Ryuji Higashikubo, Carolyn J. Anderson, Buck E. Rogers   +6 more
doaj   +1 more source

Acromegaly: Beyond surgery

Indian Journal of Endocrinology and Metabolism, 2013
Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels.
Gaya Thanabalasingham, Ashley B Grossman
doaj   +1 more source

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant

Frontiers in Endocrinology, 2022
Somatostatin exhibits an inhibitory effect on pituitary hormone secretion, including inhibition of growth hormone and adrenocorticotropic hormone (ACTH), and it can have antisecretory and antitumor effects on neuroendocrine tumors (NETs) that express ...
Rosario Pivonello, Pamela N. Munster, Massimo Terzolo, Rosario Ferrigno, Chiara Simeoli, Soraya Puglisi, Utsav Bali, Andreas G. Moraitis   +7 more
doaj   +1 more source

SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.

Folia Histochemica et Cytobiologica, 2010
The effectiveness of the long acting somatostatin analogues like octreotide and lanreotide depends on the expression of specific somatostatin receptors on the target cells.
Jolanta Kunert-Radek, Marek Pawlikowski, Hanna Pisarek, Robert Kubiak, Katarzyna Winczyk   +4 more
doaj   +1 more source